PT  - JOURNAL ARTICLE
AU  - Chow, Carson C.
AU  - Chang, Joshua C.
AU  - Gerkin, Richard C.
AU  - Vattikuti, Shashaank
TI  - Global prediction of unreported SARS-CoV2 infection from observed COVID-19 cases
AID  - 10.1101/2020.04.29.20083485
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.29.20083485
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20083485.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20083485.full
AB  - Estimation of infectiousness and fatality of the SARS-CoV-2 virus in the COVID-19 global pandemic is complicated by ascertainment bias resulting from incomplete and non-representative samples of infected individuals. We developed a strategy for overcoming this bias to obtain more plausible estimates of the true values of key epidemiological variables. We fit mechanistic Bayesian latent-variable SIR models to confirmed COVID-19 cases, deaths, and recoveries, for all regions (countries and US states) independently. Bayesian averaging over models, we find that the raw infection incidence rate underestimates the true rate by a factor, the case ascertainment ratio CARt that depends upon region and time. At the regional onset of COVID-19, the predicted global median was 13 infections unreported for each case confirmed (CARt = 0.07 C.I. (0.02, 0.4)). As the infection spread, the median CARt rose to 9 unreported cases for every one diagnosed as of April 15, 2020 (CARt = 0.1 C.I. (0.02, 0.5)). We also estimate that the median global initial reproduction number R0 is 3.3 (C.I (1.5, 8.3)) and the total infection fatality rate near the onset is 0.17% (C.I. (0.05%, 0.9%)). However the time-dependent reproduction number Rt and infection fatality rate as of April 15 were 1.2 (C.I. (0.6, 2.5)) and 0.8% (C.I. (0.2%,4%)), respectively. We find that there is great variability between country- and state-level values. Our estimates are consistent with recent serological estimates of cumulative infections for the state of New York, but inconsistent with claims that very large fractions of the population have already been infected in most other regions. For most regions, our estimates imply a great deal of uncertainty about the current state and trajectory of the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCCC and SV were supported by the Intramural Program of the NIH, NIDDK. RCG was supported by NIDCD, NINDS, and NSF. This work utilized the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and computer code used is publicly available https://github.com/nih-niddk-mbs/covid-sicr